550
Participants
Start Date
September 2, 2025
Primary Completion Date
April 30, 2027
Study Completion Date
May 31, 2027
SNG001
SNG001 nebuliser solution is presented as a ready-to-use aqueous solution (neutral pH) in glass syringes containing 0.65 mL of drug product solution containing 12 MIU/mL of IFNβ 1a.
Placebo
The placebo nebuliser solution is presented in glass syringes containing 0.65 mL of solution containing the same formulation as the study medication but without IFNβ 1a (i.e., only the excipients of the SNG001 solution).
NOT_YET_RECRUITING
NYU Langone Tisch Hospital, New York
NOT_YET_RECRUITING
VA Western New York Healthcare system, Buffalo
NOT_YET_RECRUITING
University of North Carolina (UNC), Chapel Hill
RECRUITING
AnMed Health Pulmonary and Sleep Medicine, Anderson
NOT_YET_RECRUITING
Emory University, Atlanta
NOT_YET_RECRUITING
NCH Pulmonary Critical Care, Naples
NOT_YET_RECRUITING
The Ohio State University (OSU), Columbus
NOT_YET_RECRUITING
Mercy St. Vincent Medical Center, Toledo
NOT_YET_RECRUITING
The Cleveland Clinic Foundation, Cleveland
NOT_YET_RECRUITING
University of Cincinnati Medical Center (UCMC), Cincinnati
NOT_YET_RECRUITING
William Beaumont Hospital, Royal Oak
NOT_YET_RECRUITING
Wayne State University, Detroit
NOT_YET_RECRUITING
Medical College of Wisconsin, Milwaukee
NOT_YET_RECRUITING
Mayo Clinic - Rochester, Rochester
NOT_YET_RECRUITING
Northwestern University, Chicago
NOT_YET_RECRUITING
Washington University in St. Louis, St Louis
RECRUITING
Baylor University Medical Center, Dallas
NOT_YET_RECRUITING
The University of Texas Health Science Center at Houston, Houston
RECRUITING
Snake River Research, PLLC, Idaho Falls
NOT_YET_RECRUITING
Lundquist Institute for Biomedical Innovation at Harbor UCLA Medical Center, Torrance
NOT_YET_RECRUITING
University of California - Davis, Sacramento
NOT_YET_RECRUITING
Oregon Health & Science University (OHSU), Portland
RECRUITING
Glasgow Royal Infirmary, Glasgow
Synairgen Research Ltd.
INDUSTRY